Your End-to-End
Biologics CDMO Partner
Clinical & Commercial Manufacturing
Mabion employs the most current technologies utilizing our longtime expertise in production of large molecules. We specialize in manufacturing sterile biotechnological products in our GMP compliant facility. Our goal is to integrate science and technology to produce mammalian cell culture based biological drug substance and drug products such as mAbs, ADCs, bsAbs and vaccines. We achieve this by implementing recombinant protein processes based on various expression systems and purification techniques.
Learn more
Your End-to-End
Biologics CDMO Partner
Fill & Finish
Mabion offers GMP-compliant aseptic fill and finish services in vial format as well as secondary packaging and serialization services for a wide range of biologic products for both small scale clinical supply and large commercial manufacturing scale. We have our own warehouse and commercial vehicle fleet, which makes us independent from external vendors.
Learn more
Your End-to-End
Biologics CDMO Partner
Process Development
Our Process and Analytics Development Teams comprise highly experienced experts in upstream and downstream as well as supporting analytics. Understanding every process variable that affects the final product is the core of our strategy. Because of this, we use the QbD-based approach connected with sophisticated analytics at the very beginning of process development. Due to our extensive experience in commercial scale manufacturing, we use technologies that can be scaled up and transferred into GMP environments.
Learn more
Your End-to-End
Biologics CDMO Partner
Drug Characterization & Release Testing
Mabion offers thorough analytical testing spanning early development, comprehensive state-of-the art molecule characterization, QTPP and biosimilarity studies, as well as release/stability testing of the clinical and commercial material (DS and DP). We cover the full method lifecycle, including method development and qualification/validation. Purity/impurities testing, advanced structural characterization using mass spectrometry, glycan analyses and multiple bioassays are available at Mabion.
Learn more
Your End-to-End
Biologics CDMO Partner
Preclinical & Clinical Analytics
We are experts in developing, transferring and validating bioanalytical methods for the evaluation of pharmacokinetics, pharmacodynamics and immunogenicity of biological drugs in accordance with the relevant ICH and primary regulatory agencies guidelines (EMA and FDA). In the dedicated facility and in accordance with GCP and GLP standards, Mabion created a panel of biological methods for the analysis of samples from preclinical and clinical trials.
Learn more
Your End-to-End
Biologics CDMO Partner
Regulatory & Consulting Services
Mabion will assist you in setting your strategy for the development of biological products, including support in scientific advice meetings with EMA and FDA. To ensure regulatory compliance, we oversee operations for the development of products, analytical methods and processes as well as through comprehensive molecule characterization and documentation. We can support your regulatory operations to efficiently and quickly move your product toward and through clinical trials, and ultimately approval and launch.
Learn more
Your End-to-End
Biologics CDMO Partner
Located in the heart of Europe & EU
Our headquarters is based in central Poland, 1.5 hours’ drive from the Warsaw airport. As one would anticipate from an EU based CDMO, we guarantee the highest levels of production and analytics standards for your business. Additionally, our “can-do” approach to our clients’ needs offers solutions to unforeseen challenges which we overcome as a team.
News
Read what’s happening at Mabion’s.
Another win for antibody-drug conjugates in breast cancer
Another win for antibody-drug conjugates in breast cancer The results of the pivotal efficacy trial of sacituzumab govitecan, an innovative antibody-drug conjugate developed by Gilead Sciences, have just been published in The Lancet, showing improved survival of HR-positive, EGFR2-negative breast cancer patients receiving the new drug. In this trial, 543 subjects were randomized to treatment […]
Updated Novavax’s COVID vaccine effectively neutralizes…
Updated Novavax’s COVID vaccine effectively neutralizes newly emerging SARS-CoV-2 variants The updated Novavax’s COVID-19 vaccine has been reported to effectively neutralize EG.5.1 and XBB.1.16.6 subvariants, which were designated as variants of interest (VOIs) by WHO and are currently circulating all over the globe (majority of COVID cases in the EU and US are now EG.5.1 […]
Market welcomes the arrival of new RSV vaccines
Market welcomes the arrival of new RSV vaccines Pfizer has announced positive decision of FDA on the approval of its protein RSV vaccine for older adults. The product is expected to be launched before the arrival of the next RSV season this winter (third quarter). After the COVID-19 pandemic and long-term isolation from various pathogens, […]
Mabion signs contract to purchase new bioreactors…
Mabion signs contract to purchase new bioreactors diversifies technology and opens to new customers On July 11th, 2023, Mabion concluded an agreement with Global Life Sciences Solutions Polands Sp. z o.o., a Cytiva group company for the purchase of a set of Xcellerex XDR bioreactors with conventional mixing technology. The contract is valued at EUR […]